JDRF has announced that it is partnering with Plureon Corporation, a biotechnology company based in Winston-Salem, N.C. that focuses on developing therapeutic applications of stem cells.
JDRF is providing $500,000 over two years of research funding aimed at developing an insulin-producing beta cell therapy product.
The results from this study may provide a new way to restore function of insulin-producing cells.
The project plans to use Plureon's technology platform to isolate adult stem cells from a Type 1 diabetes patient and re-program them to generate fully functional pancreatic beta-cells. The objective is to return the re-programmed insulin-producing cells back into the patient without the need for immunosuppressive agents, i.e., the patients own transplanted cells will be capable of glucose-dependent insulin secretion and the restoration of normal blood sugar levels.
Looks like something to keep an eye on.
Friday, February 8, 2008
New Research Project
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment